# Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4

> **NCT04246762** · PHASE1 · COMPLETED · sponsor: **R-Pharm International, LLC** · enrollment: 17 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Olokizumab
- **DRUG:** Omeprazole
- **DRUG:** Caffeine
- **DRUG:** Warfarin+ Vitamin K
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT04246762
- **Lead sponsor:** R-Pharm International, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-16
- **Primary completion:** 2022-06-08
- **Final completion:** 2022-10-26
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2024-08-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04246762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04246762, "Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04246762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*